Ashwani Verma
Stock Analyst at UBS
(4.42)
# 411
Out of 5,093 analysts
99
Total ratings
65.71%
Success rate
14.33%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Buy | $54 → $48 | $23.50 | +104.26% | 4 | Dec 8, 2025 | |
| BHVN Biohaven | Downgrades: Neutral | $26 → $11 | $10.57 | +4.07% | 5 | Nov 26, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $163 → $188 | $165.10 | +13.87% | 7 | Nov 24, 2025 | |
| ALVO Alvotech | Maintains: Buy | $13 → $10 | $5.57 | +79.53% | 1 | Nov 18, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $195 → $220 | $225.76 | -2.55% | 1 | Nov 7, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $580 → $600 | $485.67 | +23.54% | 10 | Nov 6, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $35 → $40 | $41.41 | -3.39% | 5 | Nov 6, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Neutral | $20 | $21.41 | -6.56% | 4 | Oct 28, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $50 → $43 | $39.00 | +10.26% | 3 | Oct 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $195 | $155.19 | +25.65% | 10 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $29.65 | -12.31% | 10 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $39 | $26.94 | +44.77% | 8 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $133 → $144 | $149.79 | -3.87% | 5 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $23.35 | -22.91% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $28.60 | +46.88% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $61 | $95.35 | -36.03% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $60.19 | -31.88% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.34 | -21.35% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $72.00 | +58.33% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $38.40 | -27.08% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $198.75 | -96.48% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $11.61 | +3.36% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.57 | +855.41% | 1 | Oct 11, 2022 |
Legend Biotech
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $23.50
Upside: +104.26%
Biohaven
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $10.57
Upside: +4.07%
Jazz Pharmaceuticals
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $165.10
Upside: +13.87%
Alvotech
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $5.57
Upside: +79.53%
AbbVie
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $225.76
Upside: -2.55%
United Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $580 → $600
Current: $485.67
Upside: +23.54%
Exelixis
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $41.41
Upside: -3.39%
Avadel Pharmaceuticals
Oct 28, 2025
Downgrades: Neutral
Price Target: $20
Current: $21.41
Upside: -6.56%
Harmony Biosciences Holdings
Oct 15, 2025
Maintains: Buy
Price Target: $50 → $43
Current: $39.00
Upside: +10.26%
Neurocrine Biosciences
Oct 9, 2025
Maintains: Buy
Price Target: $188 → $195
Current: $155.19
Upside: +25.65%
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $29.65
Upside: -12.31%
Sep 9, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $26.94
Upside: +44.77%
Aug 6, 2025
Maintains: Buy
Price Target: $133 → $144
Current: $149.79
Upside: -3.87%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $23.35
Upside: -22.91%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $28.60
Upside: +46.88%
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $95.35
Upside: -36.03%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $60.19
Upside: -31.88%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.34
Upside: -21.35%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $72.00
Upside: +58.33%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $38.40
Upside: -27.08%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $198.75
Upside: -96.48%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $11.61
Upside: +3.36%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.57
Upside: +855.41%